% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wankhede:290034,
      author       = {D. Wankhede$^*$ and S. Grover and P. Hofman},
      title        = {{SMARCA}4 alterations in non-small cell lung cancer: a
                      systematic review and meta-analysis.},
      journal      = {Journal of clinical pathology},
      volume       = {77},
      number       = {7},
      issn         = {0021-9746},
      address      = {London},
      publisher    = {BMJ Publ. Group},
      reportid     = {DKFZ-2024-00939},
      pages        = {457-463},
      year         = {2024},
      note         = {#EA:C070# / 2024 Jun 19;77(7):457-463},
      abstract     = {A mutation in the SMARCA4 gene which encodes BRG1, a common
                      catalytic subunit of switch/sucrose non-fermentable
                      chromatin-remodelling complexes, plays a vital role in
                      carcinogenesis. SMARCA4 mutations are present in
                      approximately $10\%$ of non-small cell lung cancers (NSCLC),
                      making it a crucial gene in NSCLC, but with varying
                      prognostic associations. To explore this, we conducted a
                      systematic review and meta-analysis on the prognostic
                      significance of SMARCA4 mutations in NSCLC.Electronic
                      database search was performed from inception to December
                      2022. Study characteristics and prognostic data were
                      extracted from each eligible study. Depending on
                      heterogeneity, pooled HR and $95\%$ CI were derived using
                      the random-effects or fixed-effects models.8 studies (11
                      cohorts) enrolling 8371 patients were eligible for
                      inclusion. Data on overall survival (OS) and
                      progression-free survival (PFS) were available from 8 (10
                      cohorts) and 1 (3 cohorts) studies, respectively. Comparing
                      SMARCA4-mutated NSCLC patients with SMARCA4-wild-type NSCLC
                      patients, the summary HRs for OS and PFS were 1.49 $(95\%$
                      CI 1.18 to 1.87; $I2=84\%)$ and 3.97 $(95\%$ CI 1.32 to
                      11.92; $I2=79\%),$ respectively. The results from the
                      trim-and-fill method for publication bias and sensitivity
                      analysis were inconsistent with the primary analyses. Three
                      studies reported NSCLC prognosis for category I and II
                      mutations separately; category I was significantly
                      associated with OS.Our findings suggest that SMARCA4
                      mutation negatively affects NSCLC OS and PFS. The prognostic
                      effects of SMARCA4-co-occurring mutations and the predictive
                      role of SMARCA4 mutation status in immunotherapy require
                      further exploration.},
      subtyp        = {Review Article},
      keywords     = {Lung Neoplasms (Other) / ONCOGENES (Other)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38702192},
      doi          = {10.1136/jcp-2024-209394},
      url          = {https://inrepo02.dkfz.de/record/290034},
}